Lipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention

Lipodystrophy at the injection sites is most common local complication of insulin therapy. The history of its study started in 1926, when first cases of lipoatrophy at the sites of insulin injections were described. As we moved to human insulin and insulin analogues, immune mediated atrophic form of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vadim V. Klimontov, Mikhail M. Lazarev, Andrey Ju. Letyagin, Dinara M. Bulumbaeva, Natalia P. Bgatova
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2020
Materias:
Acceso en línea:https://doaj.org/article/7fe9a1c09a59476c8fa484167227118d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7fe9a1c09a59476c8fa484167227118d
record_format dspace
spelling oai:doaj.org-article:7fe9a1c09a59476c8fa484167227118d2021-11-14T09:00:23ZLipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention2072-03512072-037810.14341/DM12095https://doaj.org/article/7fe9a1c09a59476c8fa484167227118d2020-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12095https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Lipodystrophy at the injection sites is most common local complication of insulin therapy. The history of its study started in 1926, when first cases of lipoatrophy at the sites of insulin injections were described. As we moved to human insulin and insulin analogues, immune mediated atrophic form of lipodystrophy has been replaced by hypertrophic one, which reflects anabolic and mitogenic effect of insulin. Lipohypertrophy at the injection sites is detected by physical examination in 40-70% of insulin-treated subjects. The detection efficiency depends on health care provider`s skills. Therefore, training of medical doctors and nurses in physical examination of injection sites seems to be reasonable. In recent years, ultrasound was introduced for diagnostics of insulin-induced lipohypertrophy. The method is more sensitive compared to palpation; ultrasound-verified lipohypertropthy was detected in more than 80% of cases. In patients with wide-spread lipohypertrophy ultrasound can be used to find suitable sites for injections (“ultrasound injection map”). Strain sonoelastography and 3D-power Doppler ultrasound can be used for quantitative estimation of rigidity and vascularization of lipohypertrophy. Both MRI and infrared images are considered as promising diagnostic tools. In a number of studies, it has been shown that the presence of lipohypertrophy is associated with high HbA1c levels, enhanced glycemic variability, «unexplained» hypoglycemia, and increased insulin doses. Thereby, lipohypertrophy aggravates the diabetes-related costs. The main risk factor for lipohypertrophy is inappropriate injection technique, including the lack of the site rotation, injections into lipodystrophic lesions, small injection area, reuse or excessive length of the needles. Accordingly, training patients in the injection technique is the basis for prevention of complication. The cessation of injections in lipohypertrophy areas and regular site rotation is essential for adequate titration of insulin dose and achievement of glycemic targets.Vadim V. KlimontovMikhail M. LazarevAndrey Ju. LetyaginDinara M. BulumbaevaNatalia P. BgatovaEndocrinology Research Centrearticlediabetes mellitusinsulininjectionssubcutaneous tissuelipodystrophyultrasonographyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 2, Pp 161-173 (2020)
institution DOAJ
collection DOAJ
language EN
RU
topic diabetes mellitus
insulin
injections
subcutaneous tissue
lipodystrophy
ultrasonography
Nutritional diseases. Deficiency diseases
RC620-627
spellingShingle diabetes mellitus
insulin
injections
subcutaneous tissue
lipodystrophy
ultrasonography
Nutritional diseases. Deficiency diseases
RC620-627
Vadim V. Klimontov
Mikhail M. Lazarev
Andrey Ju. Letyagin
Dinara M. Bulumbaeva
Natalia P. Bgatova
Lipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention
description Lipodystrophy at the injection sites is most common local complication of insulin therapy. The history of its study started in 1926, when first cases of lipoatrophy at the sites of insulin injections were described. As we moved to human insulin and insulin analogues, immune mediated atrophic form of lipodystrophy has been replaced by hypertrophic one, which reflects anabolic and mitogenic effect of insulin. Lipohypertrophy at the injection sites is detected by physical examination in 40-70% of insulin-treated subjects. The detection efficiency depends on health care provider`s skills. Therefore, training of medical doctors and nurses in physical examination of injection sites seems to be reasonable. In recent years, ultrasound was introduced for diagnostics of insulin-induced lipohypertrophy. The method is more sensitive compared to palpation; ultrasound-verified lipohypertropthy was detected in more than 80% of cases. In patients with wide-spread lipohypertrophy ultrasound can be used to find suitable sites for injections (“ultrasound injection map”). Strain sonoelastography and 3D-power Doppler ultrasound can be used for quantitative estimation of rigidity and vascularization of lipohypertrophy. Both MRI and infrared images are considered as promising diagnostic tools. In a number of studies, it has been shown that the presence of lipohypertrophy is associated with high HbA1c levels, enhanced glycemic variability, «unexplained» hypoglycemia, and increased insulin doses. Thereby, lipohypertrophy aggravates the diabetes-related costs. The main risk factor for lipohypertrophy is inappropriate injection technique, including the lack of the site rotation, injections into lipodystrophic lesions, small injection area, reuse or excessive length of the needles. Accordingly, training patients in the injection technique is the basis for prevention of complication. The cessation of injections in lipohypertrophy areas and regular site rotation is essential for adequate titration of insulin dose and achievement of glycemic targets.
format article
author Vadim V. Klimontov
Mikhail M. Lazarev
Andrey Ju. Letyagin
Dinara M. Bulumbaeva
Natalia P. Bgatova
author_facet Vadim V. Klimontov
Mikhail M. Lazarev
Andrey Ju. Letyagin
Dinara M. Bulumbaeva
Natalia P. Bgatova
author_sort Vadim V. Klimontov
title Lipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention
title_short Lipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention
title_full Lipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention
title_fullStr Lipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention
title_full_unstemmed Lipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention
title_sort lipodystrophy at the insulin injection sites: current trends in epidemiology, diagnostics and prevention
publisher Endocrinology Research Centre
publishDate 2020
url https://doaj.org/article/7fe9a1c09a59476c8fa484167227118d
work_keys_str_mv AT vadimvklimontov lipodystrophyattheinsulininjectionsitescurrenttrendsinepidemiologydiagnosticsandprevention
AT mikhailmlazarev lipodystrophyattheinsulininjectionsitescurrenttrendsinepidemiologydiagnosticsandprevention
AT andreyjuletyagin lipodystrophyattheinsulininjectionsitescurrenttrendsinepidemiologydiagnosticsandprevention
AT dinarambulumbaeva lipodystrophyattheinsulininjectionsitescurrenttrendsinepidemiologydiagnosticsandprevention
AT nataliapbgatova lipodystrophyattheinsulininjectionsitescurrenttrendsinepidemiologydiagnosticsandprevention
_version_ 1718429472040943616